Role of Growth Arrest-Specific Gene 6 in Diabetic Nephropathy

Vitamins and Hormones

Volumn 78, Issue , 2008, Pages 375-392

  Arai, Hidenori ^a   Nagai, Kojiro ^a   Doi, Toshio ^b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAS6 PROTEIN, HUMAN; GAS6 PROTEIN, MOUSE; GAS6 PROTEIN, RAT; PROTEIN KINASE B; SIGNAL PEPTIDE; UNCLASSIFIED DRUG; WARFARIN;

ANIMAL; DIABETIC NEPHROPATHY; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION; GENETICS; HUMAN; HYPERTROPHY; MESANGIUM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; RAT; REVIEW;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GENE EXPRESSION; GLOMERULAR MESANGIUM; HUMANS; HYPERTROPHY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; WARFARIN;

EID: 40949133694     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(07)00015-5     Document Type: Review

References (30)

1. Bojestig M., Arnqvist H.J., Hermansson G., Karlberg B.E., and Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N. Engl. J. Med. 330 (1994) 15-18
2. Booth S.L., and Mayer J. Warfarin use and fracture risk. Nutr. Rev. 58 (2000) 20-22
3. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., Remuzzi G., Snapinn S.M., Zhang Z., and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (2001) 861-869
4. Choudhury G.G. Akt serine threonine kinase regulates platelet-derived growth factor-induced DNA synthesis in glomerular mesangial cells: Regulation of c-fos AND p27(kip1) gene expression. J. Biol. Chem. 276 (2001) 35636-35643
5. Feliers D., Duraisamy S., Faulkner J.L., Duch J., Lee A.V., Abboud H.E., Choudhury G.G., and Kasinath B.S. Activation of renal signaling pathways in db/db mice with type 2 diabetes. Kidney Int. 60 (2001) 495-504
6. Gallus A.S., Baker R.I., Chong B.H., Ockelford P.A., and Street A.M. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis. Med. J. Aust. 172 (2000) 600-605
7. Ghosh P.M., Mikhailova M., Bedolla R., and Kreisberg J.I. Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am. J. Physiol. Renal Physiol. 280 (2001) F972-F979
8. Gooch J.L., Tang Y., Ricono J.M., and Abboud H.E. Insulin-like growth factor-I induces renal cell hypertrophy via a calcineurin-dependent mechanism. J. Biol. Chem. 276 (2001) 42492-42500
9. Gorin Y., Kim N.H., Feliers D., Bhandari B., Choudhury G.G., and Abboud H.E. Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-kinase. FASEB J. 15 (2001) 1909-1920
10. Gorin Y., Ricono J.M., Kim N.H., Bhandari B., Choudhury G.G., and Abboud H.E. Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am. J. Physiol. Renal Physiol. 285 (2003) F219-F229
11. Goruppi S., Bonventre J.V., and Kyriakis J.M. Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J. 21 (2002) 5427-5436
12. Hiromura K., Monkawa T., Petermann A.T., Durvasula R.V., and Shankland S.J. Insulin is a potent survival factor in mesangial cells: Role of the PI3-kinase/Akt pathway. Kidney Int. 61 (2002) 1312-1321
13. Hostetter T.H. Hypertrophy and hyperfunction of the diabetic kidney. J. Clin. Invest. 107 (2001) 161-162
14. Krolewski M., Eggers P.W., and Warram J.H. Magnitude of end-stage renal disease in IDDM: A 35 year follow-up study. Kidney Int. 50 (1996) 2041-2046
15. Lehmann R., and Schleicher E.D. Molecular mechanism of diabetic nephropathy. Clin. Chim. Acta 297 (2000) 135-144
16. Lloberas N., Cruzado J.M., Franquesa M., Herrero-Fresneda I., Torras J., Alperovich G., Rama I., Vidal A., and Grinyo J.M. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J. Am. Soc. Nephrol. 17 (2006) 1395-1404
17. Makino H., Yamasaki Y., Hironaka K., and Ota Z. Glomerular extracellular matrices in rat diabetic glomerulopathy by scanning electron microscopy. Virchows Arch. B Cell Pathol. 62 (1992) 19-24
18. Manfioletti G., Brancolini C., Avanzi G., and Schneider C. The protein encoded by a growth arrest-specific gene (Gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol. Cell. Biol. 13 (1993) 4976-4985
19. Nakano T., Higashino K., Kikuchi N., Kishino J., Nomura K., Fujita H., Ohara O., and Arita H. Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca(2+)-mobilizing growth factors. J. Biol. Chem. 270 (1995) 5702-5705
20. Nakano T., Kawamoto K., Kishino J., Nomura K., Higashino K., and Arita H. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: Contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem. J. 323 Pt. 2 (1997) 387-392
21. Ravid M., Brosh D., Levi Z., Bar-Dayan Y., Ravid D., and Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 128 (1998) 982-988
22. Schulman S., and Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N. Engl. J. Med. 342 (2000) 1953-1958
23. Stockelman M.G., Lorenz J.N., Smith F.N., Boivin G.P., Sahota A., Tischfield J.A., and Stambrook P.J. Chronic renal failure in a mouse model of human adenine phosphoribosyltransferase deficiency. Am. J. Physiol. 275 (1998) F154-F163
24. Utimura R., Fujihara C.K., Mattar A.L., Malheiros D.M., Noronha I.L., and Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 63 (2003) 209-216
25. Wolf G. Cell cycle regulation in diabetic nephropathy. Kidney Int. Suppl. 77 (2000) S59-S66
26. Wolf G., and Ziyadeh F.N. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 56 (1999) 393-405
27. Yanagita M., Arai H., Ishii K., Nakano T., Ohashi K., Mizuno K., Varnum B., Fukatsu A., Doi T., and Kita T. Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis. Am. J. Pathol. 158 (2001) 1423-1432
28. Yanagita M., Ishii K., Ozaki H., Arai H., Nakano T., Ohashi K., Mizuno K., Kita T., and Doi T. Mechanism of inhibitory effect of warfarin on mesangial cell proliferation. J. Am. Soc. Nephrol. 10 (1999) 2503-2509
29. Yanagita M., Ishimoto Y., Arai H., Nagai K., Ito T., Nakano T., Salant D.J., Fukatsu A., Doi T., and Kita T. Essential role of Gas6 for glomerular injury in nephrotoxic nephritis. J. Clin. Invest. 110 (2002) 239-246
30. Ziyadeh F.N. The extracellular matrix in diabetic nephropathy. Am. J. Kidney Dis. 22 (1993) 736-744